Kornimate/medical-research-clean huggingface dataset:
the effectiveness of interventions targeting self-perception of aging in older adults with subjective cognitive decline

Conditions: Subjective Cognitive Decline (SCD)

Summary: subjective cognitive decline (scd) represents the initial clinical manifestation in the disease spectrum of alzheimer's disease (ad). it represents an essential stage for early prevention and treatment of cognitive impairment, making the scd population an optimal target for prior intervention. this study aims to assess the feasibility and efficacy of an 8-week intervention targeting self-perception of aging in community-dwelling older adults with scd.

dementia, especially alzheimer's disease (ad), is a major healthcare issue in aging populations. it not only threatens the physical and mental health of older adults but also imposes significant economic and caregiving burdens on families and society. as a preclinical stage of ad, subjective cognitive decline (scd) is regarded as the optimal phase for early intervention in cognitive impairment. when confronted with the threats of physical, psychological, and social aging, older adults with scd often hold negative perceptions and emotional responses toward their own aging. they tend to attribute physical decline and memory loss to normal aging processes, overlooking controllable factors, which poses potential risks to their future cognitive outcomes, such as accelerated cognitive decline, elevated dementia risk, and increased accumulation of ad biomarkers. this study is based on the transactional model of stress and coping (tmsc) and identifies the mechanisms through which self-perception of aging influences cognitive function in older adults with scd. a comprehensive 8-week intervention program was developed to target these mechanisms. the 8-week intervention program aims to provide practical evidence for delaying cognitive decline in older adults with scd by enhancing their positive perceptions of aging.

Eligibility criteria:
inclusion criteria: * aged ≥60 years; * residing in the community for 6 months at least; * experiencing a consistent decline in self-reported cognitive abilities; * having standard cognitive test performance in the normal range; * willing to participate in this study. exclusion criteria: * having diagnosis of any neurological diseases including parkinson's disease, brain tumor, cerebral infarction, encephalitis, epilepsy, etc.; * having diagnosis of mental illness such as depression, anxiety, bipolar disorder, and schizophrenia; * with history of substance abuse or addiction; * with severe visual or hearing impairment.

Keywords: subjective cognitive decline older adults
dietary nitrate in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the acute consumption of dietary nitrate has been shown to improve exercise capacity in athletes, healthy adults and subjects with peripheral vascular disease. many copd patients have reduced exercise capacity, the investigators hypothesized that acute nitrate consumption, in the form of beetroot juice, might increase incremental shuttle walk test (iswt) distance in copd subjects.

acute consumption of dietary nitrate (as beetroot juice) has been shown to improve exercise capacity in athletes, healthy adults and subjects with peripheral vascular disease. many copd patients have reduced exercise capacity, the investigators hypothesized that acute nitrate consumption might increase incremental shuttle walk test (iswt) distance in copd subjects compared to a matched, low-nitrate drink. this study is a randomized, double-blind placebo-controlled, crossover trial. resting blood pressure, phlebotomy and iswt are performed. following completion, each subject is randomized to consume beetroot juice or placebo. 3 hours later, the same assessments are repeated by the same people. after a 7d washout, the entire protocol is repeated with the crossover beverage.

Eligibility criteria:
inclusion criteria: * information consenting out-patients with a previous physician diagnosis of copd * clinically stable * ambulatory exclusion criteria: * subjects who required supplemental oxygen for exercise * subjects with pulmonary hypertension and angina * intolerant to beetroot * insulin dependent diabetes * thyroid disease

Keywords: copd, beetroot, dietary nitrate, nitric oxide
study of genes in relation to seasonal affective disorder and major depressive disorder

Conditions: Seasonal Affective Disorder

Summary: the investigators are looking for volunteers who have a history of major depressive disorder, the winter blues, or seasonal affective disorder or healthy volunteers who do not have a history of these disorders for a research study on genetics.

the investigators are looking for volunteers who have a history of major depressive disorder, the winter blues, or seasonal affective disorder or healthy volunteers who do not have a history of these disorders for a research study on genetics. participation involves one 2-3 hour visit involving two diagnostic interviews, dna collection, and questionnaires.

Eligibility criteria:
inclusion criteria: * sad or mdd * healthy control exclusion criteria: * drug or alcohol dependence * bipolar disorder

Keywords: seasonal affective disorder major depressive disorder depression winter blues
a randomized controlled study of digitalized cognitive-behavioral intervention for childhood anxiety

Conditions: Anxiety

Summary: the aim of the study is to evaluate the effectiveness of a digitalized cognitive-behavioral treatment for anxiety among school aged children. the participants are screened from the general population, as a part of the routine school health care check-ups. half of the children with anxiety will receive the digitalized treatment program, while the other half will receive education about anxiety in internet.


Eligibility criteria:
inclusion criteria: - scoring ≥22 on scared exclusion criteria: * no access to internet * insufficient language (finnish until summer 2019, finnish and swedish from autumn 2019 onwards, when also swedish version of the intervention was available) skills * visual or hearing impairment that hinders the use of the program * the child's mental retardation, autism spectrum disorder, suicidal intentions or severe mental disorder * the child's psychotherapy (ongoing or starting within 6 months) * the child's medication (for anxiety) started / changed within 2 months * current involvement with child protection services (i.e., removal of child custody, investigation of child abuse or neglect) * parent's severe psychiatric / somatic disease or other reason that hinders the parent to actively participate in the program
leader (levocetirizine and desloratadine in allergic rhinitis)

Conditions: Rhinitis, Allergic, Perennial

Summary: two weeks study to evaluate the efficacy and safety of levocetirizine and desloratadine in patients suffering from allergic rhinitis (ar)


Eligibility criteria:
inclusion criteria: * at least 2-year history of allergic rhinitis that became symptomatic during the annual grass pollen season. * a skin test for grass pollens positive: * have rhinitis symptoms of such severity that the mean t4ss over the baseline period must be 6. exclusion criteria: * have an associated asthma requiring corticosteroid treatment, * have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,

Keywords: allergic rhinits, symptoms (sneezing, rhinorrhea, nasal/ocular pruritus, nasal congestion), leader, xyzal, levocetirizine
phase ii trial of folfoxigil versus folfoxiri as first-line therapy in patients with mcrc

Conditions: Metastatic Colorectal Cancer

Summary: a randomized phase ii trial of folfoxiri in combination with gm-csf and il-2 (folfoxigil) versus folfoxiri as first-line treatment for patients with metastatic colorectal cancer.

the triple drug regimen folfoxiri (irinotecan, oxaliplatin, fluorouracil, and folinate) for the first-line treatment of metastatic colorectal cancer has shown a significant increase in response rate and overall survival compared to folfiri and folfox. the combination of golf chemotherapy with gm-csf and il-2（golfig regimen） has shown more active than the standard folfox chemotherapy in first-line mcrc patients，through the chemoimmunomodulatory effects. so the folfoxigil chemoimmunotherapy regimen was designed with the same principle to evaluate the antitumor frontline efficacy in comparison with the folfoxiri regimen as first-line treatment of mcrc patients. this is a multicenter, randomized controlled, double-blind, phase ii trial.

Eligibility criteria:
inclusion criteria: * histological or cytological documentation of adenocarcinoma of the colon or rectum. * unresectable metastatic disease * age 18 to 75 years * eastern cooperative oncology group (ecog) performance status of 2 or lower if age 70 years or younger or ecog performance status of 0 if age 71 to 75 years * at least one measurable lesion according to response evaluation criteria in solid tumors (recist) criteria measured within 4 weeks prior to registration. * no previous chemotherapy or target therapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago). * adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: * leukocytes ≥ 3.0 x109/ l, absolute neutrophil count (anc) ≥ 1.5 x109/ l, platelet count ≥ 100 x109/ l, hemoglobin (hb) ≥9g/ dl. * total bilirubin ≤ 1.5 x the upper limit of normal (uln). * alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 5 x uln. * alkaline phosphatase limit ≤ 5x uln. * amylase and lipase ≤ 1.5 x the uln. * serum creatinine ≤ 1.5 x the uln. * calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 ml/ min. exclusion criteria: * previous palliative chemotherapy for metastatic disease * previous chemotherapy including irinotecan or oxaliplatin * symptomatic cardiac disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia * active infections * pregnancy or lactation at the time of study entry. * inflammatory bowel disease * major autoimmune diseases * acquired immunosuppression (aids or major immunosuppressive agents)
ofatumumab + chlorambucil vs chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia

Conditions: Leukaemia, Lymphocytic, Chronic

Summary: the purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated chronic lymphocytic leukemia.

chlorambucil, is currently approved for treatment of frontline chronic lymphocytic leukemia, especially, but not limited to the ailing and elderly patient population. several other more aggressive treatment options are available (e.g. fludarabine), however they are not suitable for all cll patients, especially the ailing and elderly, due to greater toxicity. ofatumumab is effective with low toxicity. the addition of ofatumumab to chlorambucil offers potentially a more effective therapy, with limited toxicity. the objective of this study was to evaluate progression-free survival (pfs), overall response and overall survival in subjects with previously untreated cll with ofatumumab added to chlorambucil versus chlorambucil.

Eligibility criteria:
inclusion criteria: * confirmed cll diagnosis and active cll requiring treatment * considered inappropriate for fludarabine-based therapy * not been treated for cll before * fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours * age 18yrs or older * signed written informed consent exclusion criteria: * prior cll therapy * abnormal/inadequate blood values, liver, and kidney function * certain heart problems, active or chronic infections, serious significant diseases, active autoimmune hemolytic anemia (aiha) requiring treatment, other current cancer or within last 5 years * cll transformation * cll central nervous system involvement * current participation in other clinical study * inability to comply with the protocol activities * lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

Keywords: safety untreated efficacy chronic lymphocytic leukemia chronic lymphocytic leukemia (cll), untreated ofatumumab oncology
antioxidative effect of plantago asiatica l. extract

Conditions: Oxidative Stress

Summary: the purpose of this study is to evaluate the antioxidant effect of plantago asiatica l. extract in subjects with mild hyperlipidemia.

the purpose of this study is to evaluate an acute effect of plantago asiatica l. extract consumption on antioxidative biomarkers in subjects with mild hyperlipidemia. subjects will intake plantago asiatica l. extract with a high fat meal for oxidative stress loading. antioxidative biomarkers will be measured after single-dose administration of plantago asiatica l. extract.

Eligibility criteria:
inclusion criteria: * adults age over 30 * bmi(body mass index) between 25 and 33 kg/m2 * total cholesterol between 200mg/dl and 250mg/dl or triglyceride between 150mg/dl and 220mg/dl or ldl-cholesterol between 130mg/dl and 165mg/dl exclusion criteria: * subject who has taken part in other clinical trials within 30 days of screening visit * subject who has taken medicines, chinese medicines and health/functional foods which can affect antioxidative biomarkers within 30days of screening visit * subject who is pregnant or breast feeding * subject who lost body weight over 4kg within 30days of screening visit * alcoholic * smoker * subject who takes excessive exercise (over 7hours/week) * subject who has hypertension(≥140/90mmhg), diabetes(fasting blood glucose ≥126mg/dl), kidney disease, hepatic disease or hyperthyroidism within 2years * subject who has an allergy to the ingredients of study product
novel topical treatment of hand dermatitis (eczema)

Conditions: Contact Dermatitis; Eczema, Contact

Summary: this study is designed as a prospective, randomized, double-blind right/left comparison of epikeia coatings to improve hand dermatitis.

hand dermatitis was chosen for investigation due to high incidence and typical symmetrical involvement that allows for right/left treatment comparisons. hand dermatitis is also important due to its implication on healthcare workers in particular, where frequent hand washing and chronic occlusion from gloving, provide a route for skin sensitization to natural rubber latex proteins increase the risk of colonization of microorganisms on the skin, and thereby increase the likelihood of contact dermatitis. this feasibility study will be performed to evaluate the efficacy of pvdf coatings in treating chronic hand dermatitis.

Eligibility criteria:
inclusion criteria: subjects must meet the following inclusion criteria: 1. 18 years of age or older; 2. have mild to moderate hand dermatitis, according to investigator global assessment (see below); 3. be generally healthy, as determined by brief medical history; 4. have a negative urine test for pregnancy if female, and use of highly effective method of birth control, such as condoms \& spermacide, implants, injectables, combined oral contraceptives, intrauterine device (iud's), sexual abstinence, or a vasectomized partner. for subjects using a hormonal contraceptive method, \[i.e., birth control pill (bcp)\], the dose and type of bcp should stay constant 1 month prior to enrollment and throughout the study, and 5. be capable of understanding and signing the consent form. exclusion criteria: subjects will be excluded from the study if they: 1. have clinically relevant allergic or irritant contact dermatitis and the inability to avoid exposure; 2. have severe and very severe hand dermatitis according to the investigator global assessment; 3. have severe vesiculation or bullae; 4. have a history of psoriasis, contact urticaria, and/or pustular diseases of the hands; 5. have had therapy of the hands with potent topical corticosteroids within one month of enrollment; 6. have used systemic treatment with oral retinoids, corticosteroids, or with puva within the 8 week period prior to the beginning of the study 7. have a history of alcoholism or drug abuse; 8. have a history or current evidence of a chronic or infectious skin disease; and 9. are pregnant or lactating females, or using method of birth control that does not comply with highly effective methods of birth control listed under inclusion criteria; pregnant or lactating females, or using method of birth control that does not comply with highly effective methods of birth control listed under inclusion criteria.

Keywords: mild to moderate hand dermatitis hand eczema
radiation therapy plus chemotherapy in treating patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy combined with chemotherapy may kill more tumor cells. purpose: phase ii trial to study the effectiveness of brachytherapy followed by external-beam radiation therapy plus chemotherapy in treating patients who have pancreatic cancer that cannot be removed surgically.

objectives: * determine the response/remission rate, survival, and degree of local control from interstitial colloidal phosphorus p32 followed by external beam radiotherapy and chemotherapy in patients with unresectable pancreatic cancer. outline: patients are stratified according to prior therapy (yes vs no). patients receive dexamethasone intratumorally, then macroaggregated albumin and interstitial phosphorus p32 intratumorally. most patients receive a second course of this brachytherapy. patients then proceed to chemoradiotherapy beginning 7-14 days after brachytherapy. radiotherapy is administered 5 days a week for 6.4 weeks. fluorouracil iv is administered every other day for 4 doses during weeks 1 and 2. patients are followed monthly for 1 year then every 3 months thereafter. projected accrual: a total of 48 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically proven unresectable adenocarcinoma of the pancreas limited to the head, body, or tail of the pancreas * diameter no greater than 5 cm * volume no greater than 66 ml * no ascites (with or without tumor cells) * no endoscopically proven tumor penetration of duodenum or stomach patient characteristics: age: * 18 and over performance status: * karnofsky 70-100% hematopoietic: * wbc at least 3,000/mm3 * platelet count at least 100,000/mm3 * hemoglobin at least 9 g/dl (transfusion allowed) hepatic: * no hepatic disease * at least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis suspected * no vascular occlusion of portal system renal: * creatinine no greater than 1.5 mg/dl * bun no greater than 25 mg/dl other: * no crohn's disease, ulcerative colitis, or other inflammatory bowel disease * not pregnant prior concurrent therapy: biologic therapy: * not specified chemotherapy: * if prior chemotherapy, test dose of colloidal phosphorous p32 administered prior to attempted treatment endocrine therapy: * not specified radiotherapy: * no prior radiotherapy to pancreas, liver, or upper gastrointestinal tract surgery: * no complete surgical resection * no splenectomy

Keywords: stage i pancreatic cancer stage ii pancreatic cancer stage iii pancreatic cancer adenocarcinoma of the pancreas
fodmaps and refractory gerd

Conditions: Gastro-esophageal Reflux Disease (GERD)

Summary: the aim of this study is to determine the effects of a low fermentescible oligosaccharides disaccharides monosaccharides and polyols (fodmap) diet in patients with documented refractory gerd on proton pump inhibitor (ppi) therapy.

colonic fermentation has been shown to influence oeso-gastric motility : increased gastric relaxation, increased rate of lower esophageal sphincter relaxation. experimental increased colonic fermentation (fos in diet) increase the occurrence of reflux events in patients with gerd. the aim of this study is to compare the low-fodmap diet and classical gerd dietary recommendations (avoid fatty meals, head of bed elevation etc..) in patients with refractory gerd symptoms.

Eligibility criteria:
inclusion criteria: * age \> 18 * affiliation to french social security * informed written consent * rdq score \> 3 * abnormal ph-impedance monitoring on ppi twice daily (since 3 months) according to normal values published by zerbib et al (cgh 2013) exclusion criteria: * pregnancy or breast feeding * women of childbearing potential without an effective method of contraception * person under guardianship * history of thoracic of abdominal surgery (excepted appendectomy and cholecystectomy)

Keywords: fodmap diet ph-impedance monitoring
multi-treatment pnn modulation for chronic rhinitis

Conditions: Chronic Rhinitis

Summary: feasibility of treatment at multiple sites with the clarifix cryoablation device for treatment of chronic rhinitis


Eligibility criteria:
inclusion criteria: * presence of moderate to severe rhinorrhea symptoms and mild to severe nasal congestion symptoms for \>3 months. * documented allergy test within the last 10 years that defines whether or not subject has allergies to perennial and seasonal allergens, or is willing to have one performed prior to study exit. * able to provide informed consent and willing to complete study activities and visits per protocol. exclusion criteria: * clinically significant anatomic obstructions that limit access to the posterior nose. * prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose. * moderate to severe ocular symptoms as determined. * history of epistaxis in the past 3 months. * history of rhinitis medicamentosa. * prior head or neck irradiation. * active or chronic nasal or sinus infection. * pregnant. * allergy or intolerance to anesthetic agent. * cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, raynaud's disease, and/or, open and/or infected wounds at or near the target tissue. * currently participating in another clinical research study. * any physical condition that, in the investigator's opinion, would prevent adequate study participation or pose increased risk.